259 related articles for article (PubMed ID: 28124506)
21. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.
Matikainen N; Söderlund S; Björnson E; Pietiläinen K; Hakkarainen A; Lundbom N; Taskinen MR; Borén J
Diabetes Obes Metab; 2019 Jan; 21(1):84-94. PubMed ID: 30073766
[TBL] [Abstract][Full Text] [Related]
22. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
Russell-Jones D; Vaag A; Schmitz O; Sethi BK; Lalic N; Antic S; Zdravkovic M; Ravn GM; Simó R;
Diabetologia; 2009 Oct; 52(10):2046-55. PubMed ID: 19688338
[TBL] [Abstract][Full Text] [Related]
23. Metformin monotherapy significantly decreases epicardial adipose tissue thickness in newly diagnosed type 2 diabetes patients.
Ziyrek M; Kahraman S; Ozdemir E; Dogan A
Rev Port Cardiol (Engl Ed); 2019 Jun; 38(6):419-423. PubMed ID: 31324408
[TBL] [Abstract][Full Text] [Related]
24. GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.
Kadouh H; Chedid V; Halawi H; Burton DD; Clark MM; Khemani D; Vella A; Acosta A; Camilleri M
J Clin Endocrinol Metab; 2020 May; 105(5):1552-63. PubMed ID: 31665455
[TBL] [Abstract][Full Text] [Related]
25. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
[TBL] [Abstract][Full Text] [Related]
26. Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial.
Bouchi R; Nakano Y; Fukuda T; Takeuchi T; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
Endocr J; 2017 Mar; 64(3):269-281. PubMed ID: 27916783
[TBL] [Abstract][Full Text] [Related]
27. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study.
Perna S; Guido D; Bologna C; Solerte SB; Guerriero F; Isu A; Rondanelli M
Aging Clin Exp Res; 2016 Dec; 28(6):1251-1257. PubMed ID: 26749118
[TBL] [Abstract][Full Text] [Related]
28. Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity.
Iacobellis G; Villasante Fricke AC
J Endocr Soc; 2020 Apr; 4(4):bvz042. PubMed ID: 32190806
[TBL] [Abstract][Full Text] [Related]
29. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
[TBL] [Abstract][Full Text] [Related]
30. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
Zang L; Liu Y; Geng J; Luo Y; Bian F; Lv X; Yang J; Liu J; Peng Y; Li Y; Sun Y; Bosch-Traberg H; Mu Y
Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930
[TBL] [Abstract][Full Text] [Related]
32. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
Lee WC; Conner C; Hammer M
Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
[TBL] [Abstract][Full Text] [Related]
33. [The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].
Yan L; Wang S; Chen P; Chen C; Shao Z; Xu X; Huang Q
Zhonghua Nei Ke Za Zhi; 2015 Apr; 54(4):307-12. PubMed ID: 26268058
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes.
Tanaka K; Saisho Y; Kawai T; Tanaka M; Meguro S; Irie J; Imai T; Shigihara T; Morimoto J; Yajima K; Atsumi Y; Takei I; Itoh H
Endocr J; 2015; 62(5):399-409. PubMed ID: 25739726
[TBL] [Abstract][Full Text] [Related]
35. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
Li CJ; Yu Q; Yu P; Zhang QM; Ding M; Liu XJ; Yu DM
Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):469-76. PubMed ID: 24838155
[TBL] [Abstract][Full Text] [Related]
37. Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy.
Zaitoon H; Lubetzky R; Amir AZ; Moran-Lev H; Sagi L; Yacobi-Bach M; Borger O; Chorna E; Lebenthal Y; Brener A
Acta Diabetol; 2023 Aug; 60(8):1099-1108. PubMed ID: 37160786
[TBL] [Abstract][Full Text] [Related]
38. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
Jensterle M; Kravos NA; Pfeifer M; Kocjan T; Janez A
Hormones (Athens); 2015; 14(1):81-90. PubMed ID: 25885106
[TBL] [Abstract][Full Text] [Related]
39. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.
Feinglos MN; Saad MF; Pi-Sunyer FX; An B; Santiago O;
Diabet Med; 2005 Aug; 22(8):1016-23. PubMed ID: 16026367
[TBL] [Abstract][Full Text] [Related]
40. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.
Neeland IJ; Marso SP; Ayers CR; Lewis B; Oslica R; Francis W; Rodder S; Pandey A; Joshi PH
Lancet Diabetes Endocrinol; 2021 Sep; 9(9):595-605. PubMed ID: 34358471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
